Jeremy Pincus’ Post

Meet Hywel Evans at Reuters Pharma Customer Engagement Europe 2023 to discuss how NLP and generative AI can quickly provide insights and simplify outputs when dealing with challenges like staying up to date on trending medical topics and understanding the latest scientific information.   https://lnkd.in/eWNgUfum #MedicalAffairs #GenerativeAI #SocialMediaListening

I returned to Klick two months ago to focus on generative AI. Since then, I've been researching generative AI for pharma marketing, speaking with clients, shaping solutions with colleagues, and testing the market. Attached is a POV that reflects my learning to date. Some highlights include: 📊 Hard data and examples of existing and anticipated impact. ⏩ A proposed maturity model to guide and evaluate organizational adoption. ✅ The importance of compliance automation to unleash impact in pharma. You can download the full POV here and leave comments below: https://bit.ly/3TmnBwK #PharmaInnovation #AIInMarketing #ComplianceCopilot #OrganizationalReadiness #KlickAI

Curious about Unlocking Insights in Pharma with #AI? Thank you Techstrong.ai for sharing insights from Doron Aspitz, CEO of Verix, on the challenges faced by pharma executives in navigating vast data. The article emphasizes the necessity of #automation for continuous data refreshment, which is essential for accurate insights. Quality #ai solutions offer comprehensive analyses, providing precise insights impossible with manual methods📈💡

Attention all Pharma & Biotech professionals! You're invited to join tomorrow's webinar event: The Future of Pharmacovigilance: Exploring Automation and AI in Literature Surveillance. 📅 When? Thursday, February 22, 2024 🕤 Time? 9am ET | 10am CT | 4pm GMT 💻 Where? Anywhere Online - Zoom (link upon registration)! Explore how AI is impacting Pharmacovigilance with expert insights from Andrew Purchase and Dr Chris Bendall, featuring an exclusive demo of two pioneering AI tools. Make sure to secure your spot now and be part of the conversation! #AIforResearch #Pharmacovigilance #Research

In PM360 Magazine, Within3 expert Kristen Stih Bushka writes: "The challenge, therefore, is not just about [pharma teams] handling vast volumes of data but about ensuring that this data is leveraged effectively to guide the decision-making process." Read more about the challenges of data management amid the rise of #AI: https://hubs.la/Q02D2xw70

Scientists and researchers are coming up with great cures to many diseases and improving the quality of life for patients with many other diseases. FDA approved the first gene therapies for sickle cell disease today! But as a system we are doing a disservice to their achievements by delivering a poor patient experience. What is the point of a great medicine if 70% of the "eligible" (covered by insurance!) patients do not get access to that drug? Portals and apps do not narrow the gap. Digital conversations that support a patient's journey with education about the medicine, that help navigate the financial and insurance aspects, that provides nurse support, that provides status updates from the specialty pharmacies and conversations that support continued adherence, closes the gap! Conversational AI solutions that are integrated with underlying systems of record, that can deliver well designed conversations, that pass regulatory and compliance checks and systems that are optimized on an ongoing basis based on the data collected from these conversations can close the gap! Lifelink CEO Greg Johnsen articulates the case very well in this podcast. #specialtypharmacy #conversationalai #patientengagement

As companies continue to explore the ways AI can change their operations, it's important to be aware of the short comings of this still evolving technology: https://lnkd.in/erWpVQvN #AI #Innovation #SciSearch

Adopting AI-Driven Automation in Pharmacovigilance AND Achieving a Compelling ROI ------------------------- Arietta.ai, a leader in life science Applied AI solutions, is slated to present at the 35th Pharmacovigilance 2024 Conference in Boston, MA on May 3, 2024. Tim Howard, CEO of Arietta.ai, will delve into the pivotal role accelerated ROI plays in achieving a successful initial rollout of advanced AI by pharmacovigilance departments. "Adapting to executives' expectations regarding AI adoption is pivotal for strategic alignment within organizations. By approaching Applied AI integration in drug safety with a focused lens, we can achieve significant process enhancements while realizing a significant ROI within 12 months," commented Tim Howard. PV leaders are best served by de-emphasizing the transformative potential of Advanced AI and focusing on the pragmatic benefits of realized time and cost savings and building trust in the underlying AI models.  Quick wins that reinforce AI’s role to assist, and not replace, medical experts establish a foundation for long term success and innovation. "The adoption of LucidPV as an Applied AI point solution for pharmacovigilance supports organizational objectives and provides tangible evidence of the profound impact focused AI solutions can have on overall business success," remarked James Brooks, Chairman of Arietta.ai. Tim joins other pharmacovigilance and technology leaders to discuss prevalent challenges in drug safety data collection, analysis, signal detection, and reporting. The event provides a valuable platform for networking, knowledge exchange, and professional development. Tim's presentation is scheduled for Friday, May 3rd, at 9:40 am, followed by a Q&A session and networking opportunities. For further inquiries or to schedule a meeting, contact us here: https://lnkd.in/gUtBQish. Additional details about the conference are available at https://lnkd.in/eypUV5y7.

"How will AI be used in pharmaceutical drug discovery and clinical development?" It's a question I hear a lot. I do believe AI is going to have a massive positive impact on our industry, eventually. But unfortunately, the "Discover A New Drug" button is still very far away. Rather, I think AI in the near-term will help decrease the costs and time associated with the hundreds of small daily tasks organizations do to execute a clinical trial. In a typical clinical study, there are lots of meetings scheduled, emails sent, documents created, listings generated, and data cleaned for analysis. I've mentioned a few ideas on where I think AI might help in previous posts. Basically, all the "small stuff" adds up. If we could reduce the seemingly inconsequential tasks that collectively demand a substantial amount of people's time by 90%, then the overall cost savings over the course of a clinical study would be immense. And to make that happen, we will probably not need to use AI trained on a model with a gazillion parameters. Microsoft made big step in September with the open-source release of Phi1.5. Theoretically the model will be less expensive to train and run because it's small. It benchmarks well and that seems like a win-win. So let's see if smaller models and AI can "sweat the small stuff", giving R&D teams more time to focus on the science and positive clinical outcomes for patients.   https://lnkd.in/eF4FNBP5 #AI #LLM #pharma #clinicaldatamanagement #analytics